Akkermansia muciniphila, a beneficial gut bacterium, prevents intervertebral disc degeneration through a sophisticated delivery system involving extracellular vesicles carrying the effector protein B2UKX5. Mendelian randomization analysis established a causal inverse relationship between Akkermansia abundance and disc degeneration risk, while clinical data confirmed that reduced fecal Akkermansia levels correlated with increased spinal disc deterioration severity. The bacterium's protective effects were mediated specifically through extracellular vesicles, as pharmacologic inhibition of vesicle secretion abolished the benefits. This discovery represents a paradigm shift in understanding the gut-spine connection, revealing a direct molecular pathway where beneficial microbes can influence musculoskeletal health through targeted protein delivery. The findings have immediate clinical relevance given that low back pain affects over 500 million people globally. Unlike traditional approaches targeting inflammation or mechanical factors, this research suggests that restoring gut Akkermansia populations or delivering B2UKX5 protein could address disc degeneration at its source. The specificity of this mechanism—confirmed across multiple mouse models and validated in human samples—positions microbiome modulation as a novel therapeutic strategy for preventing age-related spinal deterioration and associated chronic pain.